MA39259B1 - Sel de camsylate - Google Patents
Sel de camsylateInfo
- Publication number
- MA39259B1 MA39259B1 MA39259A MA39259A MA39259B1 MA 39259 B1 MA39259 B1 MA 39259B1 MA 39259 A MA39259 A MA 39259A MA 39259 A MA39259 A MA 39259A MA 39259 B1 MA39259 B1 MA 39259B1
- Authority
- MA
- Morocco
- Prior art keywords
- dementia
- salt
- syndrome
- disease
- camsylate salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Un sel de camsylate de (ir,l 'r,4r)- 4-méthoxy-5"-méthyl-6'-(5-(prop-l-yn-lyl) pyridin-3-yl]-3 'h-dispiro(cyclohexane-l ,2' -inden-l '2'-imidazole]-4" -amine, des compositions pharmaceutiques contenant le sel et des utilisations thérapeutiques du sel pour traiter des pathologies associées à l'a~ telles que la maladie d'alzheimer, le syndrome de down, l'angiopathie ~-amyloïde et des états tels que la démence y compris la démence d'origine mixte vasculaire et dégénérative, la démence présénile, la démence sénile et la démence associée à la maladie de parkinson, la paralysie supranucléaire progressive ou la dégénérescence cortico-basale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662592P | 2012-06-21 | 2012-06-21 | |
PCT/GB2013/051606 WO2013190302A1 (fr) | 2012-06-21 | 2013-06-20 | Sel de camsylate |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39259A1 MA39259A1 (fr) | 2017-12-29 |
MA39259B1 true MA39259B1 (fr) | 2018-09-28 |
Family
ID=48746084
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39259A MA39259B1 (fr) | 2012-06-21 | 2013-06-20 | Sel de camsylate |
MA37666A MA37666B1 (fr) | 2012-06-21 | 2014-12-10 | Sel de camsylate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37666A MA37666B1 (fr) | 2012-06-21 | 2014-12-10 | Sel de camsylate |
Country Status (42)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
WO2016055858A1 (fr) | 2014-10-07 | 2016-04-14 | Astrazeneca Ab | Composés et leur utilisation en tant qu'inhibiteurs de bace |
JP6546410B2 (ja) * | 2015-02-23 | 2019-07-17 | ローム株式会社 | 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム |
TW201742625A (zh) | 2016-03-15 | 2017-12-16 | 阿斯特捷利康公司 | 組合療法 |
TW201740944A (zh) * | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
CN113573709A (zh) * | 2019-03-14 | 2021-10-29 | 阿斯利康(瑞典)有限公司 | 用于体重减轻的兰比斯特 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
WO2002098462A1 (fr) | 2001-06-01 | 2002-12-12 | Ono Pharmaceutical Co., Ltd. | Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
WO2005094822A1 (fr) | 2004-03-22 | 2005-10-13 | Eli Lilly And Company | Derives de pyridyle et leur utilisation en tant qu'antagonistes du recepteur de mglu5 |
EP1896478B1 (fr) | 2005-06-14 | 2014-05-21 | Merck Sharp & Dohme Corp. | Inhibiteurs d'aspartyl protéase |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
CN101360716A (zh) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
US20080318929A1 (en) | 2005-12-21 | 2008-12-25 | Barbosa Antonio J M | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta |
WO2007100536A1 (fr) | 2006-02-24 | 2007-09-07 | Wyeth | COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE |
EP2032542A2 (fr) | 2006-06-12 | 2009-03-11 | Schering Corporation | Inhibiteurs d'aspartyl protéase hétérocycliques |
WO2008076043A1 (fr) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Nouveaux 2-amino-5,5-diaryl-imidazol-4-ones |
US20090325993A1 (en) | 2007-02-01 | 2009-12-31 | Nadia Mamoona Ahmad | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders |
RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
WO2009100169A1 (fr) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4 |
FR2929943B1 (fr) * | 2008-04-15 | 2010-09-24 | Inst Rech Developpement Ird | Sels de quinoleines 2-substituees |
ES2433223T3 (es) | 2008-07-28 | 2013-12-10 | Eisai R&D Management Co., Ltd. | Derivados de espiroaminodihidrotiazina |
EP2324032B1 (fr) | 2008-08-19 | 2014-10-01 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-sécrétase |
TWI385175B (zh) | 2008-09-11 | 2013-02-11 | Amgen Inc | 作為β-分泌酶調節劑之螺旋-三環化合物及其使用方法 |
AU2010223937B2 (en) | 2009-03-13 | 2015-01-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
UY32751A (es) | 2009-07-02 | 2011-01-31 | Astrazeneca Ab | Imidazoles sustituidos y uso de los mismos |
AR077365A1 (es) | 2009-07-02 | 2011-08-24 | Astrazeneca Ab | Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta |
EP2539322B1 (fr) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de la bêta-secrétase |
WO2011123674A1 (fr) | 2010-03-31 | 2011-10-06 | Array Biopharma Inc. | Composés pour traiter des maladies neurodégénératives |
WO2011130741A1 (fr) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Composés pour le traitement de maladies neurodégénératives |
EP2601197B1 (fr) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Composés d'amino-iso-indole, d'amino-aza-iso-indole, d'amino-dihydro-isoquinoléine et d'amino-benzoxazine en tant que modulateurs de la bêta-sécrétase et leurs méthodes d'utilisation |
UY33627A (es) | 2010-09-24 | 2013-04-30 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
US20120157448A1 (en) | 2010-11-22 | 2012-06-21 | Adam Cook | Compounds for treating neurodegenerative diseases |
US8415483B2 (en) * | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
-
2013
- 2013-06-13 US US13/916,754 patent/US10548882B2/en active Active
- 2013-06-19 AR ARP130102162 patent/AR091495A1/es unknown
- 2013-06-20 PE PE2014002451A patent/PE20150670A1/es active IP Right Grant
- 2013-06-20 AU AU2013279109A patent/AU2013279109B2/en active Active
- 2013-06-20 HU HUE13733415A patent/HUE033376T2/en unknown
- 2013-06-20 IN IN10088DEN2014 patent/IN2014DN10088A/en unknown
- 2013-06-20 DK DK13733415.7T patent/DK2864316T3/en active
- 2013-06-20 CN CN201610570484.2A patent/CN106279102A/zh active Pending
- 2013-06-20 BR BR112014031531-0A patent/BR112014031531B1/pt active IP Right Grant
- 2013-06-20 PL PL13733415T patent/PL2864316T3/pl unknown
- 2013-06-20 EP EP16162104.0A patent/EP3064494A1/fr not_active Withdrawn
- 2013-06-20 ES ES13733415.7T patent/ES2618939T3/es active Active
- 2013-06-20 AP AP2014008137A patent/AP2014008137A0/xx unknown
- 2013-06-20 PT PT137334157T patent/PT2864316T/pt unknown
- 2013-06-20 CA CA2875589A patent/CA2875589C/fr active Active
- 2013-06-20 SG SG11201407934UA patent/SG11201407934UA/en unknown
- 2013-06-20 UA UAA201412619 patent/UA114196C2/uk unknown
- 2013-06-20 KR KR1020147035069A patent/KR102123708B1/ko active IP Right Grant
- 2013-06-20 WO PCT/GB2013/051606 patent/WO2013190302A1/fr active Application Filing
- 2013-06-20 JP JP2015517850A patent/JP2015520221A/ja active Pending
- 2013-06-20 NZ NZ727045A patent/NZ727045A/en not_active IP Right Cessation
- 2013-06-20 RU RU2014148305A patent/RU2638175C2/ru active
- 2013-06-20 LT LTEP13733415.7T patent/LT2864316T/lt unknown
- 2013-06-20 MA MA39259A patent/MA39259B1/fr unknown
- 2013-06-20 SI SI201330561A patent/SI2864316T1/sl unknown
- 2013-06-20 EP EP13733415.7A patent/EP2864316B1/fr active Active
- 2013-06-20 BR BR122016014302-3A patent/BR122016014302B1/pt active IP Right Grant
- 2013-06-20 AP AP2017009693A patent/AP2017009693A0/en unknown
- 2013-06-20 CN CN201380033030.6A patent/CN104411697B/zh active Active
- 2013-06-20 MX MX2014014709A patent/MX354214B/es active IP Right Grant
- 2013-06-20 RS RS20170236A patent/RS55815B1/sr unknown
- 2013-06-20 NZ NZ702742A patent/NZ702742A/en not_active IP Right Cessation
- 2013-06-21 TW TW106115007A patent/TWI639591B/zh not_active IP Right Cessation
- 2013-06-21 TW TW102122259A patent/TWI588140B/zh not_active IP Right Cessation
-
2014
- 2014-11-25 TN TN2014000491A patent/TN2014000491A1/fr unknown
- 2014-11-25 DO DO2014000268A patent/DOP2014000268A/es unknown
- 2014-12-08 IL IL236131A patent/IL236131A0/en active IP Right Grant
- 2014-12-10 MA MA37666A patent/MA37666B1/fr unknown
- 2014-12-11 CR CR20140571A patent/CR20140571A/es unknown
- 2014-12-11 CL CL2014003374A patent/CL2014003374A1/es unknown
- 2014-12-16 PH PH12014502803A patent/PH12014502803B1/en unknown
- 2014-12-18 EC ECIEPI201432215A patent/ECSP14032215A/es unknown
- 2014-12-18 CO CO14278352A patent/CO7151486A2/es unknown
- 2014-12-18 NI NI201400146A patent/NI201400146A/es unknown
-
2015
- 2015-01-20 ZA ZA2015/00408A patent/ZA201500408B/en unknown
- 2015-07-22 HK HK15106985.7A patent/HK1206349A1/zh not_active IP Right Cessation
-
2016
- 2016-03-14 PH PH12016500498A patent/PH12016500498A1/en unknown
- 2016-04-29 CR CR20160202A patent/CR20160202A/es unknown
- 2016-06-28 AR ARP160101953A patent/AR105176A2/es unknown
-
2017
- 2017-03-06 HR HRP20170359TT patent/HRP20170359T1/hr unknown
- 2017-03-08 ME MEP-2017-61A patent/ME02633B/fr unknown
- 2017-03-13 CY CY20171100314T patent/CY1119505T1/el unknown
- 2017-11-03 AU AU2017254965A patent/AU2017254965B2/en not_active Ceased
-
2018
- 2018-02-09 JP JP2018021595A patent/JP6509393B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39259A1 (fr) | Sel de camsylate | |
DOP2017000030A (es) | COMPUESTOS DERIVADOS DE ESPIRO 1,2-IMIDAZOL Y SU USO COMO INHIBIDORES DE beta-SECRETASA (BACE) | |
EA201291366A1 (ru) | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) | |
MA38071B1 (fr) | Formes cristallines d'un inhibiteur de facteur xia | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
EA201291435A1 (ru) | Производные 5,6-дигидро-2h-[1,4]оксазин-3-иламина в качестве ингибиторов бета-секретазы (bace) | |
MY151246A (en) | Benzofuranyl derivatives | |
MX2014006752A (es) | Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina. | |
EA201390932A1 (ru) | ПРОИЗВОДНЫЕ 5,6-ДИГИДРОИМИДАЗО[1,2-а]ПИРАЗИН-8-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (ВАСЕ) | |
ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
UA109800C2 (xx) | ПОХІДНІ 6,7-ДИГІДРОПІРАЗОЛО$1,5-a]ПІРАЗИН-4-ІЛАМІНУ, КОРИСНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
UA109687C2 (xx) | ПОХІДНІ 3,4-ДИГІДРОПІРОЛО$1,2-a]ПІРАЗИН-1-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MY165209A (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
WO2010080757A3 (fr) | Combinaisons avec un agoniste alpha-4-bêta-2 nicotinique | |
CO7160082A2 (es) | Un método para mejorar la función hepática | |
CO7160083A2 (es) | Método de reducción de peso | |
EA201791439A1 (ru) | ПРОИЗВОДНЫЕ ГЕТЕРОЦИКЛИЛАЛКИНОВ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРО 5-ГО ПОДТИПА (mGluR5) | |
TH167610A (th) | อนุพันธ์ 6-ไดฟลูออโรเมทิล-5, 6 ไดไฮโดร-2h-[1,4]ออกซาซิน-3-เอมีน | |
FR3022245B1 (fr) | Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation | |
CL2015000442A1 (es) | Compuestos derivados de acilguanidinas espirociclicas, inhibidores de la actividad de la enzima beta-secretasa (bace1); compuestos intermediarios; composicion farmaceutica; y uso para tratar un trastorno o enfermedad seleccionado de alzheimer, trisomia 21 (sindrome de down), demencia senil, parkinson y glaucoma, entre otros. | |
CL2008000668A1 (es) | Compuestos derivados de 3-ciano-4-(4-fenil-piperidin-1-il)piridin-2-ona; proceso de preparacion; composicion farmaceutica que los comprende; y su uso para tratar trastornos del sistema nervioso central. | |
NO20091117L (no) | 3,4-dihydrobenzo[1,2,3]tiadiazin-1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte derivater og deres anvendelse |